Long noncoding RNAs (lncRNAs) represent a vast unexplored genetic space that may hold missing drivers 3 of tumourigenesis, but few such "driver lncRNAs" are known. Until now, they have been discovered 4 through changes in expression, leading to problems in distinguishing between causative roles and passenger 5 effects. We here present a different approach for driver lncRNA discovery using mutational patterns in 6 tumour DNA. Our pipeline, ExInAtor, identifies genes with excess load of somatic single nucleotide 7 variants (SNVs) across panels of tumour genomes. Heterogeneity in mutational signatures between cancer 8 types and individuals is accounted for using a simple local trinucleotide background model, which yields 9 high precision and low computational demands. We use ExInAtor to predict drivers from the GENCODE 10 annotation across 1112 entire genomes from 23 cancer types. Using a stratified approach, we identify 15 11 high-confidence candidates: 9 novel and 6 known cancer-related genes, including MALAT1, NEAT1 and 12 SAMMSON. Both known and novel driver lncRNAs are distinguished by elevated gene length, evolutionary 13 conservation and expression. We have presented a first catalogue of mutated lncRNA genes driving cancer, 14 which will grow and improve with the application of ExInAtor to future tumour genome projects. 15 16 17 18 19 2
Introduction
1 Whole genome sequencing makes it possible to comprehensively discover the mutations, and the mutated 2 genes, that are responsible for tumour formation. By sequencing pairs of normal and tumour genomes from 3 large patient cohorts, projects such as the ICGC (International Cancer Genome Consortium) and TCGA 4 (The Cancer Genome Atlas) aim to create definitive driver mutation catalogues for all common cancers
The landscape of driver lncRNAs across 23 tumour types 23 To comprehensively discover candidate lncRNA drivers, ExInAtor was run on the 23 tumour types 24 described above. We adopted some analysis strategies to account for the relatively shallow nature of the 25 data and our consequently weak statistical power to find driver genes. First, in order to discover both cancer-26 specific and ubiquitous driver genes, ExInAtor was run on each dataset in distinct configurations: (1) 27 grouping samples by tumour type ("Tumour Specific"), (2) pooling together the entire set of tumours within 28 each of the two projects ("Pancancer") and (3) pooling data across both projects ("Superpancancer"). 29 Second, we used sample stratification to boost sensitivity. This approach is commonly used when 30 statistical power is reduced by multiple hypothesis testing (25, 26) . LncRNA genes were divided into two 31 groups of different sizes, and each was treated independently during multiple hypothesis correction. This 32 reduces the burden on resulting false discovery rate estimates. As a reference set, we curated 45 33 experimentally-validated cancer-related lncRNAs from the scientific literature, henceforth "Cancer-Related 34 LncRNAs" (CRLs) (File S3). All CRL genes belong to GENCODE v19 annotation. Remaining filtered 35 lncRNAs are referred to as "Non-CRL" (File S4). Summary statistics of the gene sets used are shown in 36   Table 1 . 37 At a Q value (false discovery rate) cutoff of 0.1, we discovered a total of 15 lncRNAs (6 and 9 from 38 CRL and non-CRL, respectively) ( Fig. 2A) (Files S5 and S6) and 24 protein-coding genes (File S7). Relaxing the cutoff to Q<0.2, we discover 10 and 27 CRL and non-CRL lncRNAs, respectively. Henceforth 1 we refer to these as driver genes, and a Q-value threshold of 0.1 is assumed unless stated otherwise. 2 ExInAtor predicted a total of five lncRNA driver genes in Alexandrov tumours, nine in TCGA and two in 3 Superpancancer (one of them already detected in Pancancer TCGA). The greatest numbers of drivers 4 predicted in individual tumours were three apiece in Breast and Kidney Chromophore (Fig. 2D) . 5 Several findings suggest that false positive prediction rates are low. Reported P values closely 6 follow the expected null distribution for the majority of genes (a full set of Quantile-quantile (QQ) plots 7 can be found in File S8). Furthermore, while a number of tumour types display a small number of putative 8 driver lncRNAs that strongly deviate from the null expectation (exemplified by Breast cancer sample in 9 Fig. 2B ), other samples yield no candidates at all (eg Liver cancer, Fig. 2C ). In general, inspection of QQ 10 plots shows a tendency for deflation of P values (File S8). To further test false discovery rates, we reran 11 these analyses on tumour data that had been randomised using two different methods (see Materials and 12 Methods for details). ExInAtor predicted no lncRNA drivers in either dataset (grey dots in Figs. 2B&C and 13 File S8). Together these data point to a rather conservative statistical model, which may discard some bona 14 fide drivers. A comprehensive set of predictions across all analyses can be found in File S9.
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ExInAtor identifies known and novel lncRNA driver genes 17 ExInAtor's sensitivity is demonstrated by its identification of altogether six CRL genes. These are: 18 MALAT1, NEAT1, PCA3, BCAR4, lncRNA-ATB (CTD−2314B22.3) and the recently-discovered 19 melanoma driver SAMMSON (RP11−460N16.1) ( Table 3 ). The latter was detected in stomach 20 adenocarcinoma, and we found that it is also present in stomach RNAseq (File S10). The majority of 21 candidates were found in tumour-specific analysis (Fig. 3A) . Nevertheless, two CRL lncRNAs, NEAT1 and 22 MALAT1, were identified in Pancancer analysis, consistent with a general role in tumourigenesis: both are 23 long, unspliced and nuclear-retained lncRNAs with demonstrated roles across a range of cancer types (9). 24 As shown in Fig. 3B , the NEAT1 exon region experiences an elevated mutation rate across cancers, when 25 compared to its flanking background regions. NEAT1 was identified in a recent study of liver cancer 26 genomes, and as the authors pointed out, it cannot be ruled out that it is identified through increased local 27 mutation rate (27) . 28 One important potential source of false positive signal in this study could be elevated mutational 29 rates in DNA regulatory elements, such as enhancers, which happen to overlap the exon of a lncRNA 30 annotation. Such cases would be expected to produce driver lncRNAs, where all mutations are concentrated 31 in a single exon. This would be indistinguishable from bona fide driver lncRNAs that have an important 32 functional domain located in a single exon. To investigate this further, we inspected the exon-level 33 mutational density of all candidate lncRNAs (File S11). Intriguingly, we find at least two cases where 34 mutations are elevated across multiple exons, but not intervening introns (Figs. 3C&D) . Altogether of 13 35 multi-exonic candidate lncRNAs, five have mutations in more than one exon. This supports the 36 interpretation that, for these cases at least, mutations cause gain-or loss-of-function in mature lncRNA 37 transcripts, and not through disruption of a DNA-encoded element. 38 Amongst the novel candidate driver genes were a number of intriguing cases with various 39 characteristics of functionality, none of which have been described in the scientific literature. In Figure 3F 40 we highlight one case, RP11-820L6.1, whose promoter is characterised by canonical histone modifications, 41 7 obvious evolutionary conservation and the recruitment of transcription factors. Most notably, the master 1 tumour suppressor transcription factor and regulator of several cancer lncRNAs, P53, is bound within the 2 first intron (28). 3 We further sought to establish the degree of overlap between ExInAtor-predicted driver genes and 4 candidates predicted by transcriptomic analyses. Two previous studies to identify cancer-related lncRNAs 5 have searched for differentially-expressed transcripts in cancer transcriptome data from microarrays and 6 RNA sequencing (8, 12) . From each study we extracted those transcripts that overlap the filtered geneset 7 used here, retrieving a total of 80 and 186 genes from the Du et al and Iyer et al ("MiTranscriptome") 8 studies, respectively (Files S12 and S13) (8, 12) . Three genes are identified by both ExInAtor and 9 MiTranscriptome (PCA3, NEAT1 and MALAT1) (P=0.0026, Chi-square with Yates' correction test) and 10 another with Du et al (PCA3) (P=0.5, Chi-square with Yates' correction test) (File S14). It should be noted 11 that all these genes belong to the CRL set. MiTranscriptome and Du share 11 genes (P<=0.0001, Chi-square 12 with Yates' correction test). This surprising discordance of driver gene prediction between studies, in 13 addition to their lack of overall intersection with the published CRL set, suggests that (1) these large-scale 14 predictions have considerable false negative rates, and (2) that available catalogues of cancer-related 15 lncRNAs, represented by the CRL set, are incomplete. 16 We searched for independent evidence of cancer roles for ExInAtor-predicted candidates.
17
Importantly, we separately considered (1) the entire set of candidates, including known CRL genes, and
18
(2), the novel ExInAtor candidates alone. This ensures that findings are not biased by the inclusion of 19 experimentally-verified CRL drivers amongst candidate gene sets. We first tested the frequency with which 20 candidates are affected by copy number variants (CNVs) across matched cancers (29). We found that all 21 candidates, and novel candidates alone, both display a trend to have elevated rates of copy number variation 22 ( Fig. 3E ). We also investigated whether candidates are more proximal to germline cancer mutations (29).
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Once more, we observe a trend for candidates to be more likely to be proximally located to such mutations 24 than expected by chance. Although the small numbers involved do not generally reach statistical 25 significance, these findings are additional evidence that ExInAtor predictions, either including or excluding 26 known cancer-related lncRNAs, are involved in tumour progression.
28
ExInAtor identifies known protein-coding cancer genes 29 Although ExInAtor was designed with lncRNAs in mind, it makes no use of functional impact 30 predictions and hence is agnostic to the protein-coding potential of the genes it analyses. We took advantage 31 of this versatility to further test ExInAtor's precision, by comparing predictions to the gold-standard 32 catalogue of the Cancer Gene Census (CGC) (24). CGC is a manually-curated and regularly-updated 33 annotation of genes whose somatic mutations have been associated with cancer. CGC genes represent a 34 subset of 545 genes (File S15) (2.7%) of the entire GENCODE set of 20,314 studied here (File S16) ( Table   35 1). 36 We ran ExInAtor using protein-coding gene annotations, without stratification. Altogether, a total 37 of 24 protein-coding drivers were identified at a false discovery rate cutoff of Q<0.1. Of these, 38% are 38 CGC genes (indicated in red, Fig. 4A ). This represents enrichment of 14-fold over random expectation 39 (P<=0.0001, Chi-square with Yates' correction test). The most significantly enriched gene in this analysis 40 is TP53, the most frequently mutated across cancers and identified in previous exome sequencing projects 41 (16) . TP53 exons display an obvious and consistent enrichment of somatic mutations in both datasets, 1 clustered in exons 4 and 7-11 ( Fig. 4D ). This TP53 signal is observed in both Pancancer and multiple 2 individual cancer types.
3 Several of the 15 non-CGC genes identified have evidence for cancer roles: ANKRD18A in lung 4 cancer (30), DDX3X and PBRM1 in various cancers (31), HPSE2 in thyroid carcinoma (32), MYO5B in 5 gastric cancer (33). These findings suggest that ExInAtor precision may be better than implied by the 6 analysis of CGC genes alone. 7 We examined the performance of ExInAtor, in terms of the percent of predicted genes that belong 8 to CGC, at a series of Q value thresholds ( Fig. 4B ) (File S17). Shown are separate analyses for all cancer 9 types (expressed as mean prediction per cancer), and various pancancer combinations. These show that, 10 although the number of predicted genes are low, they tend to have far higher rate than that 2.7% expected 11 by random chance, even at a Q value threshold of 0.1.
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In summary, ExInAtor performs well in identifying known cancer related genes at high precision 13 from a protein-coding training set ~10 times larger than CRL lncRNAs.
15
ExInAtor is competitive with tools designed for protein-coding genes 16 Next we compared ExInAtor to a series of well-known pipelines for identification of protein-coding 17 drivers: MutSig (17), OncodriveFM (22) and OncodriveClust (34). In side-by-side analyses on identical 18 Alexandrov Pancancer data, we found that ExInAtor has low sensitivity (ie makes few predictions), but has 19 excellent precision. In fact, its predictions contain a higher percentage of CGC genes than the other methods 20 ( Fig. 4C and File S18). For example, at a cutoff of Q<0.1, ExInAtor predicts 3 genes (of which 2 are known 21 drivers), compared to 4 known drivers out of 39 for MutSig, 11 known drivers out of 104 for
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OncoDriveClust and 59 known drivers out of 589 for OncodriveFM ( Fig. 4C ). Furthermore, comparing 23 the top 30 candidates detected at several cutoffs (File S19), the majority of genes detected by ExInAtor are 24 also detected by at least one other method. 25 We also compared the four programs' performance on real and simulated Pancancer data, displayed 26 as Q-Q plots in Files S8 and S20. Again, ExInAtor performs relatively well: its predictions on true data 27 mirror the expected distribution quite well, and true P values are smaller than for simulated data. ExInAtor 28 predictions appear to be conservative, having a tendency for moderately deflated P values. In contrast, other 29 methods tend to perform worse, being either strongly deflated (MutSig), inflated (OncodriveFM) or 30 predicting less in true than randomised data (OncodriveClust). In summary, despite not employing any 31 information from protein-coding sequence to inform its predictions, ExInAtor is surprisingly competitive 32 with existing methods in the identification of coding driver genes. In particular, its predictions have low 33 sensitivity (possibly many false negatives) but high precision (a high fraction of true positives). This lends 34 weight to the accuracy of ExInAtor's lncRNA predictions. LncRNAs are predicted as drivers at higher rates compared to coding genes 37 We were interested in the overall rates of prediction of lncRNAs and protein-coding genes, as well 38 as their apparent tumour-specificity. Known driver genes are highly variable with respect to their tumour-39 type specificity. TP53 mutations are found across a wide range of cancers, while other drivers are only 1 mutated in single tumour types (16, 31) . In this analysis, we detected no lncRNAs in more than one tumour 2 (File S21). In contrast, two coding genes were discovered in two independent cancer types, while TP53 was 3 identified in no less than 9. Interestingly, a higher fraction of lncRNAs was predicted as driver genes than 4 protein coding: 0.25% and 0.11%, respectively. These figures are likely to be strongly influenced by both 5 the low sensitivity of ExInAtor discussed above and by the sparse data. In future, many more genes are 6 likely to be identified in multiple cancers when deeper data is available. Nevertheless these findings suggest 7 that lncRNA are mutated in cancer at a rate similar to, or higher than protein-coding genes. Returning to the driver lncRNAs identified by ExInAtor, we next asked whether any features 11 distinguish these from other lncRNAs. Previous studies of lncRNA have used features such as evolutionary 12 conservation and expression as proxies for functionality (35, 36) . Furthermore, previous research on protein-13 coding cancer genes showed that their genes and their processed transcripts tend to be longer than average 14 (37). 15 We compiled a series of features and, for each one, asked to what extent it differs between the CRL 16 genes and all other lncRNAs. The full set of results, plotted by magnitude of difference and statistical 17 significance, are shown in Figure 5A . It is clear that CRL genes are distinguished by a diverse range of 18 features. They are transcribed from longer genes, and have longer mature transcripts ("exonic length").
19
They are under stronger evolutionary constraint: their promoters and exons are more evolutionarily 20 conserved across a range of evolutionary distances. Their steady state RNA levels are higher and more 21 variable across human tissues. Finally, they are also more likely to be proximal to a binding site of the P53 22 tumour suppressor. In contrast, there is no difference in genic or exonic GC content between CRLs and 23 other genes.
24
Having established a series of cancer lncRNA-specific features, we asked whether these features 25 are also present in ExInAtor candidate genes. We were particularly interested in whether novel candidates 26 (ie non-CRL) share these characteristics, since this would represent an independent test for the value of 27 ExInAtor predictions. Therefore we compared the features of three gene groups: CRL lncRNAs, all 28 ExInAtor candidate genes, and novel ExInAtor candidates alone. These groups were compared to the null 29 set of genes, represented by the entire set of remaining Gencode lincRNAs ("All other genes").
30
In Figure 5B are shown the results across seven selected features. ExInAtor candidates, in common 31 with CRL, have longer genes and transcripts than lincRNAs in general (P=4E-8, P=6E-4, respectively, 32 Wilcoxon test). Surprisingly, and in contrast to CRL genes, ExInAtor candidates have significantly lower 33 GC content (P=7E-3), and higher repetitive sequence content (P=0.03). Finally, for features of evolutionary 34 conservation of both promoter and exon, in addition to steady-state RNA levels, we find that novel 35 candidates display a similar trend as CRL genes, although these do not reach statistical significance 36 (P>0.05). In summary, and pending future replication with larger gene sets, it appears that novel ExInAtor 37 predicted cancer genes share a number of distinguishing features with known cancer lncRNAs, consistent 38 with being bona fide driver genes. The GENCODE v19 lncRNA catalogue was downloaded in GTF format from 3 (www.gencodegenes.org) (4,38), and comprises 13,870 genes. A number of filtering steps were applied to 4 this list. First, only intergenic genes (having no transcripts overlapping protein-coding genes on the opposite 5 strand, or within 10 kb at their closest point on the same strand) were retained (6,308). Second, any lncRNA 6 gene with transcripts of uncertain protein-coding potential were removed, leaving 5,887 genes (see below 7 for details). Third, we included several cancer-related lncRNAs from the scientific literature, resulting in a 8 final set of 5,914 lncRNA genes (Table 1 and Files S3 and S4). Note that literature genes may violate the 9 two filters above, but must have a GENCODE identifier. This set of filtered lncRNAs is used throughout.
10
The protein-coding gene catalogue was also obtained in GTF format from GENCODE v19 (38).
11
From this annotation, all genes with biotype "protein-coding" were selected, resulting in 20,314 genes and 12 145,518 transcripts. Finally, all transcripts not having biotype "protein-coding" were removed, reducing 13 the transcripts to 81,702. (Table 1 and File S16).
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Somatic mutation data curation 16 Whole-genome cancer somatic mutations were obtained in BED format from two sources: 10 17 cancers described in Alexandrov et al (20) , and 14 cancers from TCGA (1). In addition, we included an 18 additional dataset of 100 stomach adenocarcinoma (STAD) with the Alexandrov dataset (39), resulting in 19 an original set of 22,877,059 mutations. Only single nucleotide somatic mutations and indels of length 1 20 were retained (97.7% of the total somatic variants), hereafter referred to as "mutations". AML and ALL 21 cancers from the Alexandrov dataset were removed due to their low number of genomes and mutations.
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Statistics on the remaining cancers can be found in Table 2 . Both mutation datasets were prefiltered in order 23 to remove possible misannotated germline SNPs. First, any mutations identical to an entry in dbSNP 146 24 "common" (>1% frequency) were removed, leaving 22,128,594 mutations (96.7%). Second, any recurrent 25 mutations, having the same nucleotide change observed in the same location more than once, were collapsed 26 and treated as a single event, resulting in a final set of 20,837,263 mutations (91.1%).
28
Assessing the protein-coding potential of lncRNA 29 All GENCODE v19 lncRNA transcripts were tested for protein-coding potential with CPAT (40) 30 at default settings. Any gene having one or more transcripts predicted to be protein-coding (coding potential 31 >= 0.364) was removed from further analysis. The ExInAtor workflow can be divided into the following steps: exon and background definition, 6 mutations mapping, sub-sampling of background region, gene filtering by mutation counts and statistical 7 analysis ( Fig. 1) . 8 Exon / Background definition (File S1-A-B-C): The full set of exons from all transcripts belonging 9 to a gene are merged. The remaining genic space is then defined as background, which is extended to both 10 sides of the gene according to the window length parameter. In the present study, this value was set at 10 11 kb throughout. Regions overlapping exons from any other gene are removed from this background region.
12
The coordinates of non-overlapping exons and background regions are saved in BED format. The total 13 exonic and background nucleotide length is calculated. Gene filtering by mutation counts: Mutation data are sporadic and of low density, potentially 24 resulting in inflated P values. To avoid this, ExInAtor accepts a user-defined minimum number of exonic 25 and background mutations, below which lncRNAs will not be considered. These cutoffs may be defined by 26 the user, with the default filter (used in the present study) discarding genes with less than 1 exonic mutations 27 or 1 background mutations. This is the starting point for calculations of statistical significance of enrichment of exonic 36 mutations using the hypergeometric distribution, which describes the probability of obtaining a given 37 number of successes in a given number of draws without replacement from a finite population of a specific 38 size. It is important to note that the positions corresponding to each genome are counted independently, 1 meaning that the total gene length N is defined as gene length multiplied by the number of genomes. n is 2 treated similarly. Statistical significance is estimated for a gene to have that many or more exonic mutations, 3 then are corrected for multiple hypothesis testing using the Benjamini-Hochberg procedure, which controls 4 the False Discovery Rate (FDR), here indicated by "Q". Two distinct methods were used to create trinucleotide-aware simulations of tumour mutations. In 11 the first method ("Fixed window reassignment"), the genome was divided into fixed partitions of 50 kb.
Mutations were randomly assigned to another genomic location with the same reference trinucleotide and 13 surrounding nucleotides for substitutions and indels, respectively. In the second method ("Sliding window 
Visual inspection and validation of candidates' mutations 21
To verify the quality of the mutation calling, we visually validated 12 single somatic mutations 22 from 4 candidates. First, we downloaded a SAM file of the surrounding regions of each mutation (+/-2kb) 23 with the BAM Slicer tool from CGHUB (https://cghub.ucsc.edu/); then we opened those files with IGV to 24 check the reads supporting the mutations (File S22) (41).
26
Comparison of cancer features 27 We obtained the list of lncRNA genes proximal to cancer-related germline SNPs from data were used to quantify Gencode v19 genes using the GRAPE pipeline (42) . Considering only genes that 25 are expressed (RPKM>0) at least in one tissue we described the mean, the maximum and the variance of 26 RPKM expression values across tissues. The percent of expressed genes for a given group represents the 27 total number of genes that are expressed at least in one tissue compared to the total number of genes of the 28 given group.
29
P53 analysis: We obtained ChIP data for p53 binding sites from (28). Binding maps from the two available 30 timepoints were merged. We attempted to assess a possible link between cancer driver lncRNAs and p53 31 binding site regions in two different ways. We first analysed whether the position of CRL genes in the 32 genome tend to be closer to p53 binding site regions compared to non-CRL genes. To this aim, we 33 calculated the nucleotide distance from the promoter of the gene (defined as explained before) to the closest 34 p53 binding site region for all CRL and non-CRL genes. As an alternative, we compared the probability of 35 finding a p53 binding site close to a TSS for CRL and non-CRL genes: for each we counted how many 36 genes out of the total contain at least one predicted p53 binding site region within a window of 100kb, 37 centred on the TSS. Here we have presented ExInAtor, to our knowledge the first method specifically designed to 2 identify cancer driver lncRNAs from tumour genome cohorts. ExInAtor aims to address the unique 3 opportunity of comprehensively discovering cancer driver lncRNAs within and across tumour types using 4 mutation data generated by projects such as TCGA and ICGC.
5
We have presented the results of scans across the two most substantial tumour genome sequencing 6 cohorts presently available, the Alexandrov and TCGA datasets, altogether comprising more than 1000 7 genomes from 23 cancer types. In addition to successfully retrieving at nine known protein coding drivers 8 (38% of total predictions) and six published cancer-related lncRNAs (40% of predictions), we identify for 9 the first time a total of nine novel lncRNA driver genes at low false positive rates (0.1 FDR). These novel 10 candidates share with known cancer lncRNAs a series of features including evolutionary conservation, 11 normal tissue expression and gene length. They also tend to be proximal to germline cancer SNPs and have 12 increased probability of lying in CNV regions, lending weight to their association with tumourigenesis.
13
Together these observations lend weight to the idea that ExInAtor predicts bona fide driver lncRNAs. The 14 true test of these predictions must await experimental validation in cell lines and animal models.
15
The distinguishing features of cancer-related lncRNAs are reminiscent of similar findings for 16 protein coding genes (37). Evolutionary conservation and high steady-state RNA levels are generally 17 interpreted in this context as evidence for functionality of lncRNAs (35, 36) . The significance of other 18 features is less clear, and we should be careful to consider possible non-biological factors. In the case of 19 gene length, it is likely that ExInAtor has greater statistical power for longer genes, possibly explaining the 20 significantly elevated lengths of known and novel candidates. Furthermore, it is likely that the annotated 21 length of lncRNAs is correlated with their expression, since higher expressed genes have more supporting
22
ESTs and cDNAs, and hence are more complete.
23
Other observations were unexpected: the exons of novel candidate drivers have elevated repetitive 24 content and reduced GC content. Furthermore, and in contrast to the above, these features are not shared 25 with known CRL driver genes. It is unclear whether this reflects technical artefacts of the analysis, or a 26 genuine biological insight. We can think of no bias in ExInAtor, or the cancer mutation datasets, that may 27 favour gene models with these properties, although it is entirely feasible. On the other hand, transposable 28 elements have been linked to both cancer (43,44) and lncRNA functionality (45). It is attractive to 29 hypothesise that repeat-rich lncRNAs play roles in tumourigenesis and are preferentially mutated during 30 this process. Further study will be required to establish the significance of these findings.
31
At present, our understanding of how lncRNA function is encoded in sequence motifs and Furthermore, more sensitive statistical methods employing information on mutation clustering and cancer-37 specific mutational signatures will likely improve predictions.
38
We expect that future studies will yield many more candidate lncRNAs than produced here.
39
Although the datasets used represent a large proportion of all presently available tumour genomes, future 40 projects will likely be larger and produce mutation calls of better quality. For example, the upcoming 41 PCAWG project will likely produce several fold more genomes than used here, and with more sophisticated 1 mutation calling (1,46).
2
The increasing scale of cancer genome projects will place a growing emphasis on computational 3 efficiency. One of the benefits of ExInAtor is its ability to handle data with complex trinucleotide biases 4 uses a simple subsampling algorithm, and without any functional impact predictions. This simplicity has 5 the unintended benefit that ExInAtor is capable of identifying protein-coding drivers with precision 6 comparable to the best methods. Another outcome is that ExInAtor makes very low computational 7 demands: analyses for this paper were executed on a workstation running Intel Core i7 processors. 25 8 minutes were required to analyse protein coding genes in Superpancancer (the largest dataset tested here) 9 using a single core and 2,050 MB of RAM. It required just three minutes to analyse Pilocytic astrocytoma 10 with six cores and 648 MB of RAM. Together, these features make ExInAtor suited to future, large-scale 11 cancer genome sequencing projects. The number of mutations in background and exonic regions is compared by a contingency table analysis. BCL2  BCL7A  CDH1  DDX3X  FCF1  HPSE2  KCNN3  KDM6A  MYC  MYO5B  NFE2L2  PBRM1  PIK3CA  SGK1  SNX8  SOCS1  SYNRG  TP53  ZNF605 
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